Skip to main content
SpringerLink
Log in

Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer

  • Published:
Journal of Gastrointestinal Surgery

Abstract

Well-differentiated islet cell tumors can be associated with aggressive biology, resulting in early metastases to the liver. This study was carried out to determine whether survival for patients with malignant islet cell tumors and synchronous liver metastases is affected by complete surgical resection. Thirty-one patients with synchronous liver metastases from islet cell cancer underwent surgical exploration with the intent for complete tumor resection, and all patients underwent resection of the pancreatic primary. The patients were divided into two groups, those with resectable versus unresectable liver metastases. Twenty-six of 31 (84%) patients underwent complete resection of both the primary tumor and all liver metastases, and 5 (16%) patients underwent only complete resection of the pancreatic primary without liver resection. To extirpate the primary tumor, a pancreaticoduodenectomy was performed in 11 of the 26 (42%) completely resected patients and in 4 of the 5 (80%) incompletely resected patients, P = NS. The remainder of the patients underwent distal pancreatectomy. There were no statistical differences in primary tumor size, lymph node metastases, or adjuvant treatments between patients with resected and unresected liver metastases. The median overall survival for the completely resected group was 78 months, longer than the 17 months for the group with unresectable liver metastases (P = 0.06). Complete tumor resection (or the tumor biology that allows such complete resection) affords a survival advantage to patients with metastatic islet cell tumors of the pancreas. Patterns of liver metastases from islet cell tumors, specifically multiple bilobar metastases that are not amenable to resection and/or ablation, predict a poor outcome despite resection of the primary pancreatic tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J GASTROINTEST SURG 1998;2(5):472–482.

    Article  PubMed  CAS  Google Scholar 

  2. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326(8):519–523.

    Article  PubMed  CAS  Google Scholar 

  3. Steele G Jr., Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 1991;9(7):1105–1112.

    PubMed  Google Scholar 

  4. Wagman LD, Kemeny MM, Leong L, Terz JJ, Hill LR, Beatty JD, Kokal WA, Riihimaki DU. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990;8(11):1885–1893.

    PubMed  CAS  Google Scholar 

  5. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190(4):432–445.

    Article  PubMed  CAS  Google Scholar 

  6. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998;187(1):88–92.

    Article  PubMed  CAS  Google Scholar 

  7. Grazi GL, Cescon M, Pierangeli F, Ercolani G, Gardini A, Cavallari A, Mazziotti A. Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology 2000;47(32):481–486.

    PubMed  CAS  Google Scholar 

  8. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990;108(6):1091–1096.

    PubMed  CAS  Google Scholar 

  9. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003;134(6):1057–1063.

    Article  PubMed  Google Scholar 

  10. Que FG, Nagorney Dm, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995;169(1):36–42.

    Article  PubMed  CAS  Google Scholar 

  11. Ahlman H, Wangberg B, Jansson S, Friman S, Olausson M, Tylen U, Nilsson O. Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion 2000;62(Suppl). 1:59-l:68.

    Article  Google Scholar 

  12. Anthuber M, Jauch KW, Briegel J, Groh J, Schildberg FW. Results of liver transplantation for gastroenteropancreatic tumor metastases. World J Surg 1996;20(1):73–76.

    Article  PubMed  CAS  Google Scholar 

  13. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 2000;62(Suppl). 1:84-1:91.

    Article  Google Scholar 

  14. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83(11):2293–2301.

    Article  PubMed  CAS  Google Scholar 

  15. Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, Fishbein T, Emre S, Miller C, Schwartz M. Liver transplantation for neuroendocrine tumors. J GASTROINTEST SURG 2004;8(2):208–212.

    Article  PubMed  Google Scholar 

  16. Lang H, Oldhafer KJ, Weimann A, Schlitt HJ, Scheumann GF, Flemming P, Ringe B, Pichlmayr R. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997;225(4):347–354.

    Article  PubMed  CAS  Google Scholar 

  17. Sutcliffe R, Maguire D, Ramage J, Rela M, Heaton N. Management of neuroendocrine liver metastases. Am J Surg 2004;187(1):39–46.

    Article  PubMed  Google Scholar 

  18. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 1996;20(7):908–914.

    Article  PubMed  CAS  Google Scholar 

  19. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003;197(1):29–37.

    Article  PubMed  Google Scholar 

  20. Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 2002;132(6):976–982.

    Article  PubMed  Google Scholar 

  21. Jacobsen MB, Hanssen LE. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. J Intern Med 1995;237(3):269–275.

    Article  PubMed  CAS  Google Scholar 

  22. Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994;116(6):1111–1116.

    PubMed  CAS  Google Scholar 

  23. Knechtle SJ, Kalayoglu M, D’Alessandro AM, Rikkers LF. Proceed with caution: liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997;225(4):345–346.

    Article  PubMed  CAS  Google Scholar 

  24. Delcore R, Friesen SR. Gastrointestinal neuroendocrine tumors. J Am Coll Surg 1994;178(2):187–211.

    PubMed  CAS  Google Scholar 

  25. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, Ychou M, Mignon M. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993;71(8):2624–2630.

    Article  PubMed  CAS  Google Scholar 

  26. Hansel DE, House MG, Ashfaq R, Rahman A, Yeo CJ, Maitra A. MAGE1 is expressed by a subset of pancreatic endocrine neoplasms and associated lymph node and liver metastases. Int J Gastrointest Cancer 2003;33(2-3):141–147.

    Article  PubMed  Google Scholar 

  27. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms. Surgery 2003; 134(6):902–908.

    Article  PubMed  Google Scholar 

  28. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 2003;238(3):423–431.

    PubMed  Google Scholar 

  29. Maitra A, Hansel DE, Argani P, Ashfaq R, Rahman A, Naji A, Deng S, Geradts J, Hawthorne L, House MG, Yeo CJ. Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res 2003;9(16):5988–5995.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The Indiana University School of Medicine, Indianapolis, Indiana

    Michael G. House M.D., John L. Cameron M.D. & Keith D. Lillemoe M.D.

  2. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland

    Richard D. Schulick M.D., Michael A. Choti M.D. & Charles J. Yeo M.D. (The Samuel D. Gross Professor and Chairman)

  3. Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland

    Donna E. Hansel M.D., Ralph H. Hruban M.D. & Anirban Maitra M.D.

Authors
  1. Michael G. House M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John L. Cameron M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keith D. Lillemoe M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard D. Schulick M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael A. Choti M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Donna E. Hansel M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ralph H. Hruban M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anirban Maitra M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Charles J. Yeo M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles J. Yeo M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

House, M.G., Cameron, J.L., Lillemoe, K.D. et al. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg 10, 138–145 (2006). https://doi.org/10.1016/j.gassur.2005.05.004

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.gassur.2005.05.004

Key words

Search

Navigation